Editor's Note: At a recent international academic symposium, Dr. Sophie Merrick from the Medical Research Council Clinical Trials Unit at University College London (UCL) reported the Patient-Reported Outcome (PRO) data from the RAMPART trial. The study aimed to evaluate the dynamic impact of adjuvant durvalumab plus tremelimumab versus active monitoring on the quality of life (QoL) of patients with resected renal cell carcinoma (RCC).01 Background:
The Role and Challenges of Adjuvant Therapy in RCC The risk of recurrence after surgery for renal cell carcinoma (RCC) remains a critical clinical concern. While nephrectomy is the standard of care for locoregional RCC, patients at intermediate-to-high risk face high recurrence rates. The RAMPART trial—an investigator-led, international, randomized Phase 3 study—explored the efficacy of adjuvant immunotherapy compared to active monitoring. While improving clinical survival is the primary goal, understanding the impact of treatment on a patient’s daily quality of life (QoL) is essential for optimizing clinical decision-making.
02 Efficacy Review:
Significant DFS Improvement with Durvalumab plus Tremelimumab In the RAMPART trial, patients with resected intermediate- or high-risk RCC were randomized in a 3:2:2 ratio to active monitoring, durvalumab monotherapy (1 year), or durvalumab (1 year) plus tremelimumab (administered at Day 1 and Week 4).
Previously disclosed data from the intention-to-treat (ITT) population demonstrated that the durvalumab plus tremelimumab combination significantly improved disease-free survival (DFS) compared to active monitoring.
- Key Data: Hazard Ratio (HR) = 0.65, P = 0.0094.
- Survival Benefit: The landmark 3-year DFS rate was 81% for the combination arm versus 73% for the active monitoring arm.
However, safety data showed that Grade 3 or higher adverse events (AEs) occurred in 40% of the combination group, significantly higher than the 8% observed in the monitoring group. Additionally, 32% of patients in the combination arm discontinued treatment due to AEs.
03 PRO Study Design:
Multidimensional Assessment of Patient Experience The RAMPART PRO sub-study was conducted primarily in English-speaking countries, including the UK and Australia. The EORTC QLQ-C30 questionnaire was utilized at baseline, Week 16, and Month 15.
- Primary Outcome: Change in overall health and QoL from baseline to Month 15.
- Analysis Population: 329 patients consented to the PRO sub-study; 254 patients completed the baseline and at least one follow-up questionnaire (104 in the combination arm, 150 in the active monitoring arm).
- Scoring Criteria: Higher scores in functional scales and overall health represent better QoL, while higher scores in symptom scales indicate greater symptom burden. Differences were evaluated based on pre-defined EORTC clinically meaningful thresholds.
04 Dynamic Changes:
Early Decline in QoL at Week 16 At the Week 16 follow-up, the durvalumab plus tremelimumab group exhibited a notable decline in quality of life compared to the monitoring group.
- Functioning and Overall Scores: Overall health status/QoL and role functioning were significantly worse in the combination arm, exceeding clinically meaningful thresholds with statistical significance.
- Symptom Burden: Fatigue and insomnia were significantly more severe in the combination arm compared to the active monitoring arm, both meeting the criteria for clinical significance.
- Proportional Analysis: At Week 16, a significantly higher proportion of participants in the combination arm experienced a large, clinically meaningful reduction in overall health and QoL.
05 Long-term Follow-up:
Recovery and Emergent Symptoms at Month 15 The primary outcome analysis showed that from baseline to Month 15, there was no statistically significant or clinically meaningful difference in the change of overall health status and QoL between the two arms (mean difference = 1).
However, granular analysis of specific domains revealed late-emerging burdens:
- Cognition and Pain: While early functional declines appeared to improve, the combination arm reported significantly worse cognitive function and increased pain at Month 15 compared to the monitoring arm, with both metrics exceeding clinically meaningful thresholds.
06 Conclusion and Outlook:
Comprehensive Trade-offs in Clinical Benefit Dr. Sophie Merrick concluded that while the combination of durvalumab and tremelimumab provides a clear DFS benefit in the adjuvant setting for RCC, it is associated with an early decline in QoL (specifically in fatigue, insomnia, and role functioning) and late-emerging issues regarding pain and cognitive function.
Expert Recommendation: In clinical practice, the DFS benefits of this adjuvant regimen must be weighed against these PRO findings. Clinicians should prioritize monitoring immune-related adverse events and QoL during the early stages of treatment and remain vigilant regarding long-term impacts on pain and cognitive health following treatment completion. These findings provide vital evidence for shared doctor-patient decision-making.
